311 related articles for article (PubMed ID: 22305626)
21. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
22. Transperineal Template Guided Prostate Biopsy Selects Candidates for Active Surveillance--How Many Cores are Enough?
Pham KN; Porter CR; Odem-Davis K; Wolff EM; Jeldres C; Wei JT; Morgan TM
J Urol; 2015 Sep; 194(3):674-9. PubMed ID: 25963186
[TBL] [Abstract][Full Text] [Related]
23. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of transperineal template-guided prostate biopsy in 409 patients.
Symons JL; Huo A; Yuen CL; Haynes AM; Matthews J; Sutherland RL; Brenner P; Stricker PD
BJU Int; 2013 Sep; 112(5):585-93. PubMed ID: 23551500
[TBL] [Abstract][Full Text] [Related]
25. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
26. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
27. The independent impact of extended pattern biopsy on prostate cancer stage migration.
Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
[TBL] [Abstract][Full Text] [Related]
28. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
[TBL] [Abstract][Full Text] [Related]
29. Transperineal template-guided saturation biopsy using a modified technique: outcome of 270 cases requiring repeat prostate biopsy.
Ekwueme K; Simpson H; Zakhour H; Parr NJ
BJU Int; 2013 Jun; 111(8):E365-73. PubMed ID: 23714648
[TBL] [Abstract][Full Text] [Related]
30. Transperineal template-guided prostate biopsy: 10 years of experience.
Mai Z; Yan W; Zhou Y; Zhou Z; Chen J; Xiao Y; Liang Z; Ji Z; Li H
BJU Int; 2016 Mar; 117(3):424-9. PubMed ID: 25523314
[TBL] [Abstract][Full Text] [Related]
31. Accuracy of primary systematic template guided transperineal biopsy of the prostate for locating prostate cancer: a comparison with radical prostatectomy specimens.
Huo AS; Hossack T; Symons JL; PeBenito R; Delprado WJ; Brenner P; Stricker PD
J Urol; 2012 Jun; 187(6):2044-9. PubMed ID: 22498226
[TBL] [Abstract][Full Text] [Related]
32. The value of free and total prostate specific antigen in identifying patients for prostatic biopsy and its relationship to Gleason score and number of positive cores.
Bulbul MA; Khauli RB; Nasr R; Hemady K; Wazzan W
J Med Liban; 2000; 48(2):59-62. PubMed ID: 11028151
[TBL] [Abstract][Full Text] [Related]
33. Are repeat biopsies required in men with PSA levels < or =4 ng/ml? A Multiinstitutional Prospective European Study.
Djavan B; Fong YK; Ravery V; Remzi M; Horninger W; Susani M; Kreuzer S; Boccon-Gibod L; Bartsch G; Marberger M
Eur Urol; 2005 Jan; 47(1):38-44; discussion 44. PubMed ID: 15582247
[TBL] [Abstract][Full Text] [Related]
34. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
35. The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen.
Emiliozzi P; Longhi S; Scarpone P; Pansadoro A; DePaula F; Pansadoro V
J Urol; 2001 Sep; 166(3):845-50. PubMed ID: 11490231
[TBL] [Abstract][Full Text] [Related]
36. Transperineal biopsy prostate cancer detection in first biopsy and repeat biopsy after negative transrectal ultrasound-guided biopsy: the Victorian Transperineal Biopsy Collaboration experience.
Ong WL; Weerakoon M; Huang S; Paul E; Lawrentschuk N; Frydenberg M; Moon D; Murphy D; Grummet J
BJU Int; 2015 Oct; 116(4):568-76. PubMed ID: 25560926
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS
BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
[TBL] [Abstract][Full Text] [Related]
38. MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies.
Anastasiadis AG; Lichy MP; Nagele U; Kuczyk MA; Merseburger AS; Hennenlotter J; Corvin S; Sievert KD; Claussen CD; Stenzl A; Schlemmer HP
Eur Urol; 2006 Oct; 50(4):738-48; discussion 748-9. PubMed ID: 16630688
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol.
Pepe P; Aragona F
Can J Urol; 2013 Feb; 20(1):6620-4. PubMed ID: 23433132
[TBL] [Abstract][Full Text] [Related]
40. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
Djavan B; Ravery V; Zlotta A; Dobronski P; Dobrovits M; Fakhari M; Seitz C; Susani M; Borkowski A; Boccon-Gibod L; Schulman CC; Marberger M
J Urol; 2001 Nov; 166(5):1679-83. PubMed ID: 11586201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
